Stryker (SYK) Tops Q4 EPS by 14c; offers guidance

Stryker (NYSE: SYK) reported Q4 EPS of $4.01, $0.14 better than the analyst estimate of $3.87. Revenue for the quarter came in at $6.4 billion versus the consensus estimate of $6.36 billion.

GUIDANCE:

Stryker sees FY2025 EPS of $13.45-$13.70, versus the consensus of $13.47.

Based on our momentum exiting 2024, a sustained level of procedural volumes, strong demand for our capital products and our presence in healthy end markets, we expect organic net sales growth(2) to be in the range of 8.0% to 9.0% for 2025

For earnings history and earnings-related data on Stryker (SYK) click here.

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
• JPMorgan Upgrades Kolmar Korea Co Ltd (161890:KS) to Overweight
• Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028